XXXX for @entity706 and @entity1778 .

@entity1 @entity706 @entity75 @entity4269 @entity1778 @entity272
@entity272 ( @entity272 ) was used in the treatment of 33 @entity1 with @entity706 and 13 @entity1 with @entity1778 involving extensive segments of the skin surface. Twenty-two of 23 had @entity272 as a primary manifestation of @entity706 (primary @entity706 ) and 11 developed @entity75 following disseminated @entity706 (secondary cutaneous @entity706 ). A once weekly fractionation scheme was employed to irradiate the entire skin surface with 3.5 to 4 MeV electron beam from a 6 MeV linear accelerator. During each weekly session, 400 rad were delivered to the entire skin and a complete course consisted of 4-6 consecutive weekly sessions. The majority of @entity1 have been previously treated elsewhere for various periods and all @entity1 have been at risk for a median of 12 months, range from 12-117 months following @entity272 . Striking predominance of the diffuse pattern (76%) was demonstrated in both the @entity4269 and SCL. There was extracutaneous involvement in 63% (13/22) of the @entity4269 , nodal or visceral at onset of @entity272 ; median follow-up was 24 months, range 6-117 months; 20/22 (90%) of all @entity1 obtained prompt relief of symptoms and complete regression of @entity75 . Duration of cutaneous remission ranged from 6-96 months, median 18 months; in general, duration was adversely influenced by the presence of visceral involvement at onset of @entity272 . Although cutaneous response among the @entity1 with SCL and @entity1778 was equally good, many of these @entity1 were treated for palliation because of rapid progression of their disease. Once weekly treatments were highly effective, well-tolerated and no untoward immediate or late effects have been noted in the bone marrow or normal skin irradiated.
